The landscape of clinical trials is undergoing a significant transformation with the implementation of the updated ICH E6 (R3) guidelines. These changes are revolutionizing how trials are structured and conducted, placing a strong emphasis on risk-based practices, technology integration, and patient-centric outcomes. With the reorganization of the guidelines into principles and objectives, the industry is gearing up for a new era of trial design and execution. The adoption of risk-based quality monitoring (RBQM) has seen a remarkable increase, with 96% of trials now incorporating at least one RBQM component, compared to just 53% in 2019. Centralized monitoring and remote oversight have become standard practices, while Source Data Verification (SDV) is being reduced in favor of Source Data Review (SDR) as a complementary layer. The guidelines also address key aspects such as eCOA and ePRO, introducing significant changes to data privacy and remote data collection practices. As the industry navigates these changes, stakeholders are urged to embrace the evolving landscape of clinical trials and leverage technology to drive compliance, data integrity, and patient-centered outcomes.
Read more from pharmaceutical-technology.com